Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32737469
Wang WL, et al. (2020) Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52. Acta Pharmacol Sin 32737469
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S293-p - PDHA1 (human)
Modsite: TYRyHGHsMsDPGVs SwissProt Entrez-Gene
Orthologous residues
PDHA1 (human): S293‑p, PDHA1 iso2 (human): S300‑p, PDHA1 iso4 (human): S331‑p, PDHA1 (mouse): S293‑p, PDHA1 (rat): S293‑p, PDHA1 (pig): S292‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia increase
NG52 decrease
NG52 hypoxia inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, inhibited

T338-p - PDHK1 (human)
Modsite: LFNYMyStAPRPRVE SwissProt Entrez-Gene
Orthologous residues
PDHK1 (human): T338‑p, PDHK1 (mouse): T336‑p, PDHK1 (rat): T336‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
hypoxia increase
NG52 decrease
NG52 hypoxia inhibit treatment-induced increase